For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older

HUMIRA Dosing in HS

Once-weekly dosing schedule for adults and adolescents (≥ 12 years), ≥ 60 kg (132 lbs) following initial dose and every other week dosing schedule for adolescents (≥ 12 years), ≥ 30 kg to < 60 kg (66 lbs to < 132 lbs) following initial dose1

Weight-based dosing is only for adolescent patients

Dosing for adults & adolescents (≥ 12 years), ≥ 60 kg with HS1

Dosing for adolescents (≥ 12 years), ≥ 30kg to < 60 kg (66 lbs to < 132 lbs) with HS1†

Dosing Considerations1
The first injection should be given under the supervision of a healthcare professional. A patient may self-inject HUMIRA after appropriate training and monitoring by a healthcare professional.

Instruct patients to rotate injection sites and not to inject into areas where the skin is tender, bruised, red, or hard.

In clinical trials, injection site reactions (erythema and/or itching, hemorrhage, pain, or swelling) were reported in 20% of HUMIRA-treated patients vs 14% of placebo-treated patients. Most reactions were mild and did not require discontinuation.

The most common adverse reactions in HUMIRA clinical trials (incidence >10%) were: infections (eg, upper respiratory, sinusitis), injection site reactions, headache, and rash.

HUMIRA citrate-free pen

No citrate buffers, thinner needle, less pain immediately following injection compared with the HUMIRA 40 mg/0.8 mL presentation.2‡§

Recommended dosing for adolescents, 12-17 years of age, weighing at least 30 kg (66 lbs) to < 60 kg (132 lbs), with moderate to severe HS.
HUMIRA Citrate-free is available to all indicated patients in the United States. HUMIRA Citrate-free features the same safety and efficacy profile of HUMIRA you've come to count on.
§Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.
EW=every week; EOW=every other week